SCHEMBL29323756

SCHEMBL29323756

CCc1cc(NC(=O)C(=O)OCC(F)(F)F)cnc1N

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.40
▸ GPR35 Q9HC97 1/20 0.38
▸ MEN1 O00255 3/20 0.36
▸ LMNA P02545 3/20 0.36
▸ KMT2A Q03164 3/20 0.36
▸ PAX8 Q06710 2/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ HTT P42858 2/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ NPSR1 Q6W5P4 2/20 0.34
▸ S1PR2 O95136 1/20 0.34
▸ S1PR4 O95977 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ XBP1 P17861 1/20 0.34
▸ S1PR3 Q99500 1/20 0.34
▸ S1PR5 Q9H228 1/20 0.34
▸ SCN9A Q15858 1/20 0.34
▸ THRA P10827 3/20 0.33
▸ THRB P10828 3/20 0.33
▸ NPC1 O15118 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31430313 0.86 MAPT (0.51) MAPTGPR35ALDH1A1GAANPC1
SCHEMBL31430203 0.86 MAPT (0.51) MAPTGPR35ALDH1A1GAANPC1
SCHEMBL24364320 0.83 ALDH1A1 (0.38) MAPTLMNAALDH1A1HTTSMN1; SMN2
SCHEMBL29081276 0.80 AR (0.36) MAPTGPR35MEN1LMNAKMT2A
SCHEMBL24363880 0.77 GABRP (0.41) GPR35LMNARAB9APOLB
SCHEMBL30469592 0.77 GABRP (0.41) GPR35LMNARAB9APOLB
SCHEMBL30470707 0.77 MAPT (0.39) MAPTGPR35MEN1LMNAKMT2A
SCHEMBL24363766 0.77 MAPT (0.39) MAPTGPR35MEN1LMNAKMT2A
SCHEMBL31145163 0.77 MAPT (0.41) MAPTGPR35MEN1LMNAKMT2A
SCHEMBL29082076 0.77 MAPT (0.41) MAPTGPR35MEN1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 — — US disclosed
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228478-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 MAPT 2749/4885GPR35 1122/4885MEN1 142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback